Sustainable Development Goals (SDGs)

Sustainable Development Goals (SDGs), which were to build upon the Millennium Development Goals, were formally adopted as the universal, integrated and transformative 2030 Agenda for Sustainable Development, along with a set of 17 Sustainable Development Goals and 169 associated targets.

Referring to the SDG Compass, Astellas has identified issues for priority action, based on the evaluation of positive and negative SDG-related impacts across the entire value chain. Going forward, Astellas plans to contribute to the attainment of the SDGs through various business activities and measures to fulfill its corporate social responsibilities.

Identified SDGs Issues for Priority Actions 

Focus on Improving Access to Health in Four Areas 

In regard to “Goal 3: Good Health and Well-Being” under the SDGs, Astellas is addressing this goal from the viewpoint of improving Access to Health. There are many people with insufficient access to the healthcare they need due to the lack of available treatments, poverty, challenges in healthcare systems and limited healthcare information. Astellas recognizes this problem as the Access to Health issue. Astellas has identified four areas where it is working to address Access to Health issues by making full use of the strengths and technology that it has. The four areas are (1) Creating innovation, (2) Enhancing availability, (3) Strengthening healthcare systems, and (4) Improving health literacy. In doing so, Astellas will make maximum use of its partnerships in the manner of Goal 17.

In creating innovation, Astellas is working to create innovative medicines and medical solutions in disease areas with low treatment satisfaction and to deliver them to patients around the world. Moreover, Astellas has been conducting collaborative research with partners aimed at creating drugs for the treatment of tuberculosis, malaria, and neglected tropical diseases (leishmaniasis and Chagas disease) and developing the rice-based oral vaccine MucoRice against infectious diseases such as cholera and enterotoxigenic Escherichia coli (E. coli). Astellas is also working closely with partners to develop a pediatric formulation of praziquantel tablets for the treatment of schistosomiasis. 

To help enhance availability, we have established programs to assist patients facing severe financial constraints with the cost of dispensing pharmaceutical products. We also support patients by not filing or enforcing patents in countries facing significant economic challenges. 

As part of strengthening healthcare systems and improving health literacy, Astellas has participated in the Access Accelerated global partnership. This initiative aims to contribute to achieving the SDG of reducing premature mortality from non-communicable diseases by one-third by 2030. In other SDG-related initiatives, Astellas is supporting the ACTION ON FISTULA program in Kenya.